What happens to a market map when a company on it goes bust? The map doesn’t get erased. It freezes, becoming a fixed record, a snapshot of where that company sat at a specific moment. This is the difference between a fluid market ‘story’ and a static cluster ‘record’.
The Enduring Record of Placement
When a company ceases operations, its place on a market map is frozen in time, creating a permanent data point for analyzing the competitive field as it once was. Look at Pear Therapeutics. Even though they’re gone, the records still place them right alongside Tempus AI and HeartFlow because their published materials all pointed back to the same work in cardiac and evidence-based medicine. You can trace their historical position by following the public signals from sources covering Cardiac AI and Radiology AI, or in reports from CB Insights and Rock Health, all verifiable data points that exist completely outside of what the companies themselves were saying.
Cardiac AI and Radiology AI in the Historical Material
Historical materials show companies were filed under specific segments like Cardiac AI and Radiology AI. HeartFlow, for example, shows up in the “Validated General” quadrant of a healthcare AI market map, right next to Mayo Clinic AI and Viz.ai Healthcare AI Market Map 2026 Quadrant Details. It earned that spot based on published peer-reviewed outcomes, something totally separate from its marketing budget or funding rounds. The Radiology AI segment in particular just exploded. The FDA had authorized over 1,451 AI/ML medical devices by the end of 2025, and a whopping 76% of them were in radiology. But here’s the catch that people miss: roughly 95% of those authorizations came through the 510(k) clearance pathway, which only proves ‘equivalence’ to existing tech, not independent clinical validation. That kind of rapid growth on thin evidence is a serious safety concern. Seeing a name like Tempus AI pop up in records for both Cardiac AI and Radiology AI contexts also shows it was working across multiple diagnostic and analytical applications.
Publisher Signals and Their Enduring Value
You can’t just trust a company’s own press releases, which is why market maps from publishers like CB Insights and Rock Health are so useful for creating a third-party record of a company’s position. Both firms included Pear Therapeutics and Tempus AI in their healthcare AI reports, with Tempus AI even appearing on a Rock Health market entry map for companies arriving between 2020 and 2026 Rock Health Healthcare AI Market Entry Map. For an investor, this is gold because it shows how the market actually saw a company, not just how the company wanted to be seen. The methodologies are key. Placement isn’t about qualitative feelings or who has the slickest presentation. It’s driven by structural factors. A spot in a top quadrant on a healthcare AI map, for instance, is decided by published peer-reviewed outcomes, meaning you simply can’t buy your way in with marketing spend.
What a Reader Can Check Without a Vendor Conversation
The whole point of a cluster record is that you don’t need to talk to a salesperson to verify it. Any investor can follow the breadcrumbs for Cardiac AI, Radiology AI, CB Insights, and Rock Health to build a historical picture of Pear, Tempus, and HeartFlow on their own. You just have to do the work. Pull up the U.S. Food and Drug Administration’s official AI device list to check their clearance pathways (was it a flimsy 510(k)?) or search PubMed for the actual peer-reviewed papers that supposedly back up their clinical claims. This document-first approach lets you reconstruct the historical case material free from the noise of sales pitches. Even a defunct company like Pear Therapeutics leaves behind a documented position, and that record remains a solid piece of data for any real competitive analysis.
Frequently Asked Questions
How do defunct ventures still provide value for competitive cluster mapping?
When a venture ceases operations, its historical placement within a market map does not vanish. The record solidifies, offering a fixed point for analysis of the competitive landscape at a specific time. This allows for continued cluster reading, documenting where the name sat in relation to other companies.
What kind of information is used to determine a company’s placement in historical competitive cluster maps?
Historical placement in competitive cluster maps, especially for healthcare AI, is often determined by published peer-reviewed outcomes, not marketing claims or funding. Recorded signals for this frame include market segments like Cardiac AI and Radiology AI, and reports from publishers like CB Insights and Rock Health.
How can investors independently verify the historical placement of companies in competitive clusters?
Investors can independently trace recorded signals for Cardiac AI, Radiology AI, CB Insights, and Rock Health through public sources. This includes consulting public databases and reports from the U.S. Food and Drug Administration (FDA) and academic publications indexed on PubMed, which provide verifiable evidence and clearance pathways.
What is the significance of the distinction between 510(k) clearance and independent clinical validation for AI/ML medical devices?
The article notes that roughly 95% of FDA authorizations for AI/ML medical devices occurred via 510(k) clearance, indicating equivalence to existing devices rather than independent clinical validation. This distinction highlights a core safety concern regarding rapid growth with thin evidence, as 510(k) does not necessarily imply new clinical validation.